COMPANY OVERVIEW

Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. The company is also exploring voclosporin in other proteinuric kidney diseases, and is advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs.

RECENT NEWS

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Jun 22 2020, 6:05 AM EDT

STOCK OVERVIEW

Symbol: AUPH
Exchange: Nasdaq
Market Cap: 1.76b
Last Price: $15.61
52-Week Range: $3.52 - $21.93

INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and it’s quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.